Clinical Trial Update: The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether ondansetron can reduce immune checkpoint inhibitor–related toxicities in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Ondansetron (ondansetron)

Snippet

Sponsor: First Affiliated Hospital of Wenzhou Medical University | Conditions: Hepatocellular Carcinoma (HCC), IrAE | Phase 2 | Status: NOT_YET_RECRUITING